Chemogenomics and orthology‐based design of antibiotic combination therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Chemogenomics and orthology‐based design of antibiotic combination therapies ; volume:12 ; number:5 ; year:2016 ; extent:12
Molecular systems biology ; 12, Heft 5 (2016) (gesamt 12)
- Urheber
-
Chandrasekaran, Sriram
Cokol‐Cakmak, Melike
Sahin, Nil
Yilancioglu, Kaan
Kazan, Hilal
Collins, James J.
Cokol, Murat
- DOI
-
10.15252/msb.20156777
- URN
-
urn:nbn:de:101:1-2022111105373772696035
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chandrasekaran, Sriram
- Cokol‐Cakmak, Melike
- Sahin, Nil
- Yilancioglu, Kaan
- Kazan, Hilal
- Collins, James J.
- Cokol, Murat
Ähnliche Objekte (12)
Nanomedicine formulations for combination therapies
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Surgery in the combination therapies era
Combination therapies utilizing neoepitope-targeted vaccines
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies
Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
Combination therapies enhance immunoregulatory properties of MIAMI cells
CAR-T cell combination therapies in hematologic malignancies
The future of combination therapies in advanced melanoma
Nanomedicine formulations for combination therapies
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Surgery in the combination therapies era
Combination therapies utilizing neoepitope-targeted vaccines
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies
Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
Combination therapies enhance immunoregulatory properties of MIAMI cells
CAR-T cell combination therapies in hematologic malignancies
The future of combination therapies in advanced melanoma
Nanomedicine formulations for combination therapies
Antitumoral polymeric siRNA nanoformulation and pretubulysin-based combination therapies
Surgery in the combination therapies era
Combination therapies utilizing neoepitope-targeted vaccines
Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy
Novel combination therapies for BRAF-mutant melanoma
Combination therapies for cancer: challenges and opportunities
Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies
Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
Combination therapies enhance immunoregulatory properties of MIAMI cells
CAR-T cell combination therapies in hematologic malignancies